Company focuses on pediatrics
Ascent Pediatrics Inc., Wilmington, DE, a new pharmaceutical firm devoted exclusively to products for children, launched its first three products in November of 1997.
Ascent Pediatrics Inc., Wilmington, DE, a new pharmaceutical firm devoted exclusively to products for children, launched its first three products in November of 1997.
The products are Feverall,® an acetaminophen suppository brand for fever reduction and pain relief; Just for Kids⢠Vitamin Drops, a liquid multivitamin; and Pediamist,® a nasal saline mist for relief of dry nasal passages. To specifically meet the needs of children, the products were developed to taste good, require reduced dosing frequency, have minimal side-effects and employ improved delivery systems.
A sales force of 65 pediatric sales specialists will contact pediatricians nationwide about the new products and the need for increased compliance among children. The pediatric market of children under the age of 12 in the United States is estimated at approximately 47 million.
"Children are not miniature adults and their needs are not the same as adults," said Emmett Clemente, Ph.D., Ascent Pediatric's founder and chairman. "Our strategy at Ascent is to meet the challenge of developing products with the goal of increasing compliance among children. After all, what good is a medicine if a child doesn't take it?" PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
